RBCC JV Target Amarantus Presents Parkinson’s Therapeutic at CNS Summit
NOKOMIS, Fla. -- November 29, 2012
As Rainbow Coral Corp. (OTCBB: RBCC) nears a new joint venture agreement to
commercialize advances made by Amarantus BioSciences (OTCBB: AMBS), the
company’s latest target continues to seek out additional investment capital
from high-profile investors.
Amarantus Chief Science Officer John W. Commissiong recently presented his
organization’s brilliant MANF therapeutic protein for Parkinson’s disease at
the Scientific Session of CNS Summit 2012 in Boca Raton. The CNS Summit brings
together researchers, developers and investors to collaborate in bringing new
treatments to patients suffering from brain disorders.
The high-profile event put Amarantus’ proprietary, anti-apoptosis therapeutic
protein in the spotlight in front of researchers and investors from around the
“We continue to be very impressed with Amarantus’ outreach efforts toward
potential investors and clients alike,” said RBCC CEO Patrick Brown. “We look
forward to wrapping up our joint venture agreement shortly, and then our first
priority will be moving their groundbreaking therapeutics forward toward full
Both companies forswear realizing revenues from the impending
commercialization of Amarantus’ NuroPro, a sophisticated test developed to
more accurately and easily diagnose Parkinson’s disease. By cutting the
typical timeline from years to only one year, RBCC and its shareholders
believe they will see larger profits more quickly from the deal. Next in line
for commercialization will be MANF.
For more information on Rainbow BioSciences’ neurological treatment
initiatives, please visitwww.rainbowbiosciences.com/investors.html.
RainbowBioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ:AMGN),Cell Therapeutics, Inc. (NASDAQ:CTIC), Abbott Laboratories
(NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit our website at [www.RainbowBioSciences.com]. For investment
information and performance data on the company, please visit
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.